Late clinical-stage cancer therapy group Nanobiotix (EPA:NANO) has strengthened its US leadership team.
The group has appointed Dr Mihail Obrocea as the head of US clinical development and Noёl Kurdi as the director of investor relations.
Obrocea joins Nanobiotix from US-based SFJ Pharmaceuticals Group, where he held the role of vice president of Clinical & Medical Affairs.
Kurdi joins Nanobiotix from the Trout Group & Trout Capital. She served as a senior associate, providing strategic investor relations counsel to biotech companies seeking access to the US and international capital markets.
“These high level profiles will contribute to reinforce Nanobiotix’s presence in the US by strengthening its clinical development and by leveraging US investors potential to continue the growth of the company,” said the statement late Monday.
Nanobiotix has successfully filed its Investigational New Drug application in the US for its prostate cancer drug NBTXR3 and plans to initiate a Phase I/II trial in three US-based oncology sites.